research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
Search
for
Sort by
Research
540-570 / 1000+ resultsresearch Treatment of Psoriasis vulgaris with a New Retinoic Acid Derivative Ro 10-9359
The treatment cleared psoriasis in some patients but caused side effects in most.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Allergic contact dermatitis to topical brimonidine
A man developed an allergic skin reaction after using brimonidine for rosacea.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research Reversible exacerbation of obstructive sleep apnea by α1-adrenergic blockade with tamsulosin: A case report
Tamsulosin can worsen sleep apnea in some patients.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
research A Study on the Role of Tofacitinib Among Patients Treated with Alopecia Areata
Tofacitinib effectively treats Alopecia Areata.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research Tofacitinib therapy for the treatment of alopecia areata: Report of 11 patients
Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Calcipotriol/dithranol
research Evaluation of Antiarthritic and Antinociceptive Effects of Cedrol in a Rat Model of Arthritis
Cedrol may help treat rheumatoid arthritis due to its anti-inflammatory and antioxidant effects.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Clin-Alert
In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
research Dermatological drugs, topical agents, and cosmetics
Natural products like propolis are causing more skin allergies, and certain skin treatments and medications have various side effects and risks.
research Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
research 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
research Ruxolitinib found to cause eyelash growth: a case report
Ruxolitinib treatment may cause eyelash growth.
research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
research Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case‐controlled study
Topical cetirizine 1% promotes hair growth in male androgenetic alopecia patients.
research Efficacy and safety of baricitinib in patients with refractory alopecia areata
Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
research Finasteride-related suicidal ideation reported to Lareb
research Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
Dutasteride effectively treats enlarged prostate with manageable side effects.
research Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome
Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
research Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis
Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.